Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ventricular arrhythmia in congestive heart failure.

P J Podrid1, R I Fogel, T T Fuchs

  • 1Evans Medical Group, University Hospital, Boston, Massachusetts 02118.

The American Journal of Cardiology
|June 4, 1992
PubMed
Summary

Nonsustained ventricular tachycardia (NSVT) in patients with congestive heart failure (CHF) indicates a high risk for sudden cardiac death. While antiarrhythmic drugs show limited efficacy, implantable cardioverter-defibrillators may offer better protection against fatal arrhythmias.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ventricular Tachycardia in the Young Athlete: A Systematic Approach to Selection of Drug Therapy.

The Physician and sportsmedicine·2016
Same author

Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restrictions. CARE Group.

Journal of the American College of Cardiology·2001
Same author

Late occurrence of heart block after radiofrequency catheter ablation of the septal region: clinical follow-up and outcome.

Journal of cardiovascular electrophysiology·2001
Same author

Management of malignant ventricular arrhythmias and cardiac arrest.

Critical care medicine·2000
Same author

Proarrhythmia, a serious complication of antiarrhythmic drugs.

Current cardiology reports·2000
Same author

Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias.

American heart journal·2000

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Research

Background:

  • Ventricular arrhythmia, particularly nonsustained ventricular tachycardia (NSVT), is a significant risk factor for sudden cardiac death (SCD) in patients with congestive heart failure (CHF).
  • This association is well-documented in patients with dilated cardiomyopathy and recent myocardial infarction, where frequent ventricular ectopy and NSVT are common.
  • High yearly mortality rates in CHF patients are often attributed to sudden death, frequently caused by sustained ventricular tachyarrhythmia.

Purpose of the Study:

  • To review the association between ventricular arrhythmia and sudden death in patients with CHF.
  • To evaluate the effectiveness of current diagnostic and therapeutic strategies for managing ventricular arrhythmias in this population.
  • To discuss the role of antiarrhythmic drugs and alternative interventions like implantable cardioverter-defibrillators (ICDs).

Related Experiment Videos

Main Methods:

  • Review of existing studies and clinical data on ventricular arrhythmias in CHF patients.
  • Analysis of the relationship between NSVT, other ventricular arrhythmias, and sudden cardiac death.
  • Evaluation of the efficacy and limitations of diagnostic tools (signal-averaged ECG, electrophysiologic testing) and therapeutic options (antiarrhythmic drugs, ICDs).

Main Results:

  • A high prevalence of ventricular premature beats (70-95%) and NSVT (40-80%) is observed in cardiomyopathy patients with CHF.
  • NSVT presence and frequency are strongly associated with an increased risk of sudden cardiac death.
  • Conventional diagnostic methods are insufficient for identifying individuals at high risk.
  • Antiarrhythmic drugs have shown variable effects on ventricular arrhythmias and have not definitively proven to reduce sudden death, with amiodarone and beta-blockers requiring further confirmation.
  • ICDs are considered a viable option for patients with a history of sustained ventricular tachyarrhythmia.

Conclusions:

  • Ventricular arrhythmia is a common and critical issue in CHF patients, directly linked to increased sudden cardiac death risk.
  • Current antiarrhythmic therapies are limited in preventing sudden death and managing ventricular arrhythmias in CHF, often carrying significant side effects.
  • Implantable cardioverter-defibrillators represent a promising therapeutic strategy for high-risk patients who have experienced life-threatening ventricular tachyarrhythmias.